Posts in Castle Biosciences
Castle Biosciences Presents Data on Unique Genetic Test for Predicting Cancer Recurrence in Soft Tissue Sarcoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS). Results were presented in a poster session at the Connective Tissue Oncology Society Annual Meeting, November 4-7, 2015 in Salt Lake City.

Read More

Read More
Dermatology Times profiles new Castle Biosciences Melanoma test

Gene expression profiling with a commercially available test (DecisionDx-Melanoma, Castle Biosciences) provides useful prognostic information for patients with high-risk cutaneous melanoma who undergo sentinel lymph node (SLN) biopsy, and particularly for those found to be node-negative, according to a study presented at the annual meeting of the American Society for Clinical Oncology.

Read More

Read More
Castle Biosciences Announces $11.8M Financing

Castle Biosciences, Inc., a cancer-focused molecular diagnostics company, today announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences’ current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.

Read More

Read More